Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note published on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock.

Other analysts also recently issued research reports about the stock. Chardan Capital reaffirmed a buy rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reaffirmed an outperform rating and issued a $9.00 price target on shares of Gain Therapeutics in a report on Tuesday, April 23rd.

Gain Therapeutics Stock Up 1.5 %

GANX stock opened at $1.38 on Thursday. The company has a market cap of $24.91 million, a P/E ratio of -0.92 and a beta of 0.35. Gain Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.33. The company’s 50-day moving average price is $1.95 and its 200 day moving average price is $3.20. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. On average, research analysts expect that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.